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Glomerulonephritis refers to a collection of primary renal
disorders and those secondary to a systemic disease, all charac-
terized by inflammation within the glomerulus. Given the un-
derlying immunologic nature of these disorders, they are rou-
tinely treated with corticosteriods and various cytotoxic agents.
Although in many instances such therapies are successful, they
are associated with significant morbidity; as such, alternatives
are clearly necessary. Our understanding of the pathogenesis
of immunologic glomerular diseases has grown remarkably, in
large part from the study of rodent disease models. Fundamen-
tal to each disorder is the development of an antigen-specific
immune response followed by the effector stage of inflamma-
tion. To block the immune response, antigen-specific therapy
can be used to induce tolerance, such as through the use of
double-stranded DNA molecules in lupus nephritis. Since other
antigen systems are less well characterized, inducing a more
generalized impairment in the immune response by blocking
costimulatory molecules CD40-CD154 and CD28-CD80/86 is a
growing approach to treat various immunologic disorders and
transplantation. To reduce glomerular inflammation, a variety
of effector systems have been targeted, including complement,
cytokines/chemokines, adhesion molecules, and mediators of
cellular proliferation. Of these, antibodies targeting C5 in the
complement system, and antibody and receptor antagonists of
tumor necrosis factor-a (TNF-a) have already been used in
glomerular disorders with some promise. Less specific block-
ade of receptor-mediated events stimulated by platelet-derived
growth factors and cell cycle proteins may soon be applied to
glomerulonephritis. Finally, interruption of fibrosing pathways,
which lead to glomerulosclerosis and interstitial fibrosis com-
mon to the end-stage of all glomerulonephritis, is the subject of
intense effort which may yield effective biologic therapies. In
spite of all these advances, we still are dependent on steroids
and cytotoxics to treat glomerulonephritis. To get past this, we
must devote significant resources to take observations made in
basic research laboratories to develop therapeutics and prove
their utility in human disease.
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The term glomerulonephritis was initially coined by
Klebs [1] and has come to represent a group of diseases
occurring either as a primary renal disorder or a sec-
ondary manifestation of a systemic disease state [2] (Ta-
ble 1). The fundamental abnormality that links these dis-
eases is the pathologic finding of inflammation within the
glomerulus. Although these diseases can take on various
forms, the renal manifestations of hematuria, proteinuria,
and impaired glomerular filtration tend to be in common
to all. Since the function of the glomerulus is to form a
protein- and cell-free ultrafiltrate from the blood passing
through its capillaries, these features of glomerulonephri-
tis reflect the limited ways impaired glomerular function
can be manifested. Despite these similarities, even the
most common variants of these disorders can have an un-
predictable disease course which can make clinical man-
agement problematic.
The number of existing cases of end-stage renal dis-
ease (ESRD) caused by glomerulonephritis increased in
the United States by 55% in the period between 1990 and
2001 to over 50,000 [3]. Interestingly however, the accu-
mulation of new ESRD cases from glomerulonephritis
has actually decreased recently, by about 12% in the pe-
riod from 1995 to 2001 [3]. The exact reason for the latter
is unclear, although the improvement in the use of non-
specific immunosuppression could be one explanation as
will be discussed.
HISTORICAL BACKGROUND
Hippocrates (460 to 375 BC) suggested that the pres-
ence of floating bubbles and a thick fatty coating on the
urine surface was indicative of kidney disease. From then,
all the way up to the middle of the last century, the con-
cept that there could be specific therapy for glomerular
diseases did not exist, save for anecdotal reports like the
use of asparagus, celery, cumin, and cucumber potion by
Galen (130 to 200 AD) [1], or potassium bitartarate by
Cotugno in 1765 to treat dropsy [4]. Thomas Addis, in his
book Glomerular Nephritis published in 1949 [5], pro-
vided a detailed account of the management of glomeru-
lar diseases and advocated the importance of “rest” as
treatment for the diseased kidney, and reducing renal
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Table 1. Causes of glomerulonephritis
Primary glomerular diseases
IgA nephropathy
Pauci-immune glomerulonephritisa
Antiglomerular basement membrane antibody diseaseb
Membranoproliferative glomerulonephritis (types I, II, and III)
Secondary glomerular diseases
Postinfectious glomerulonephritis
Lupus nephritis
Wegener’s granulomatosisa
Microscopic polyangiitisa
Cryoglobulinemiac
Henoch-Scho¨nlein purpura
aAntibody-reactivity with cytoplasmic antigens (ANCA)-associated;
bIncludes Goodpasture’s syndrome when pulmonary involvement; cMost often
hepatitis C virus-related
“work load” of urea excretion by decreasing dietary pro-
tein intake and lowering urea production, an idea that is
keenly debated to this day.
It was not until 1950 that Luetscher and Deming [6], in
what could be regarded as among the earliest published
reports, described the use of cortisone in nephrotic syn-
drome. In this series, six of the 11 treated patients had
a decline in proteinuria with an increase in creatinine
clearance to a varying extent. In the same period the
first report on the use of nitrogen mustard in glomeru-
lonephritis by Chasis, Goldring and Baldwin [7] was pub-
lished, which was soon followed by a case series by Taylor,
Corcoran, and Page [8], describing their experience in ten
patients, seven of whom showed a complete or partial re-
sponse as judged by reduction of edema and proteinuria,
though in most cases improvement in urea clearance was
not observed. The rationale for the use of nitrogen mus-
tard in these reports rested on the belief that glomeru-
lonephritis was an immunologic disorder and could
result from an antigen-antibody reaction [9, 10]. The sub-
sequent widespread availability of corticosteroids and
their demonstrated capacity to relieve many clinical man-
ifestations of glomerular diseases is thought to have led
to the abandonment of other available but more toxic
agents for over a decade.
It was apparent from the initial reports on the treat-
ment of glomerulonephritis with steroids that not all pa-
tients responded to this treatment. At around the same
time, renal biopsies were becoming standard, which al-
lowed pathologists to characterize renal diseases by his-
tologic appearance [2, 11]. It became clear that children
with nephrotic syndrome, with glomeruli that appeared
normal by light microscopy, had an excellent response to
steroids. The response to steroid treatment in other forms
of glomerular diseases in children as well as adults was less
certain and life expectancy in certain diseases like lupus
nephritis and Henoch-Scho¨nlein purpura after the clini-
cal onset of renal disease was often reduced to less than a
year [12, 13]. Following these observations, a strong case
for trying other lines of treatment, however toxic, was jus-
tified by the grave prognosis especially in diseases thought
Table 2. Nonspecific immunomodulatory agents for
glomerulonephritis
Glucocorticoids
Cyclophosphamide
Azathioprine
Chlorambucil
Mycophenolate mofetil
Cyclosporine
Tacrolimus
Rapamycin
15-deoxyspergualin
Leflunomide/FK778
FTY720
Plasma exchange
Intravenous immunoglobulin
Stem cell transplant
to have an immunologic basis. Thus, there was the intro-
duction of agents such as 6-mercaptopurine, azathioprine,
chlorambucil, and cyclophosphamide, either individually
or in combination, with or without steroids as treatment
for glomerulonephritis [13–17].
Since these earlier observations nearly 40 years ago,
three major advances have occurred. First, controlled
clinical trials have been performed which have extended
upon these anecdotal reports and have validated the effi-
cacy of such nonspecific immunosuppressive therapy for
glomerulonephritis as well as providing treatment proto-
cols that minimize risk while maximizing efficacy. Second,
newer immunosuppressive agents such as cyclosporine,
tacrolimus, and mycophenolate mofetil have been tested
and shown to be efficacious in different forms of glomeru-
lar diseases, such as lupus nephritis [18–21]. These agents
are considered selective immunosuppressives, the major
advantage being a reduction in undesirable side effects.
Finally, adjunctive treatments, such as the use of strict
blood pressure control, protein restriction, and fish oil
(as a rich source of eicosapentenoic acids) have come
into common use. There is no doubt the former is crucial,
particularly with agents that affect angiotensin II, while
the latter two remain controversial.
Other attempts at immunomodulation have been at-
tempted in glomerulonephritis, including the use of
plasma exchange, intravenous immunoglobulins (IVIG),
and stem cell transplantation. Overall, it would seem
these are either not terribly effective or too extreme to
justify their routine use in all but selected cases (such
as the routine use of plasma exchange in Goodpasture’s
syndrome). After all, the renal consequence of glomeru-
lonephritis is the development of ESRD for which ad-
equate replacement therapies exist. Table 2 summarizes
the current immunosuppressive therapies in existence for
glomerulonephritis.
TARGETS OF FUTURE THERAPY
The purpose of the remainder of this review will be
to discuss the future treatment of glomerulonephritis. At
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this point, we will once again recognize that glomeru-
lonephritis is a heterogenous collection of disease enti-
ties (Table 1). However, fundamental to each of these
disorders is immune-mediated damage to the glomeru-
lus involving development of an antigen-specific immune
response followed by the effector stage of inflammation.
This fact has been the rationale for the use of nonspecific
immunosuppression discussed previously but also guides
therapeutic principles targeting each stage of this immune
response.
The antigen inciting glomerulonephritis can be derived
from the host, such as in the case of DNA in lupus nephri-
tis (recognizing DNA is one of many potential autoanti-
gens in lupus nephritis) or type IV collagen in Goodpas-
ture’s syndrome, or can be exogenous antigen, including
those from infectious agents like group A streptococci or
hepatitis C virus. In many cases, the antigen is unknown,
such as in membranoproliferative glomerulonephritis
and IgA nephropathy. In the vasculitides characterized by
antibody reactivity with neutrophil cytoplasmic antigens
(ANCA), the etiologic role of this antigen-antibody sys-
tem remains controversial. Regardless of specific antigen,
the immune response requires a coordinated effort be-
tween antigen-presenting cells and lymphocytes, involv-
ing antigen-specific proteins and ancillary costimulatory
molecules. Another important issue concerns how anti-
gens exogenous to the glomerulus arrive in the glomeru-
lus. Often this involves the complexities of how circulat-
ing and locally formed immune complexes are processed.
Once the immune response has formed and antigen (and
antibody in many cases) have arrived in the glomeru-
lus, the resulting glomerulonephritis involves a host of
humoral and cellular effector systems, each of which is
a potential target in the quest to dampen inflammation.
Not only can there be infiltration of cells extrinsic to the
glomerulus, intrinsic glomerular cells have the clear po-
tential to be involved in disease, and can elaborate a host
of inflammatory molecules as well as undergo phenotypic
changes and proliferate. Finally, the development of a fi-
brotic phenotype culminating in the histological picture
of glomerulosclerosis (and interstitial fibrosis) represents
the terminal stage of glomerulonephritis of any cause.
Table 3 lists various mediator systems involved in
glomerulonephritis which have been considered as sites
for therapeutic intervention. Although circumstantial ev-
idence for their involvement has been gathered from
the study of humans, by far most experimental evidence
has been generated in the experimental animal, includ-
ing the development and use of specific therapeutics,
some of which are also listed in this table. It is impor-
tant to note that although the experimental animal has
provided for remarkable insights into disease pathogen-
esis, many instances of therapy applied to animals have
their limitations insofar as they involve treatment of a
homogenous population (in many cases, genetically iden-
Table 3. Immune/inflammatory systems involved in
glomerulonephritis and relevant therapeutics
Immune response
Antigen LJP 394 (abetimus)
B lymphocytes Anti-CD20 (rituximab)
Costimulation
CD40-CD154 Anti-CD154 (IDEC-131 and BG9588)
CD28-CD80/CD86 CTLA4 (CTLA4-Ig, LEA29Y)
Anti-CD80 (h1F1) and anti-CD86 (h3D1)
Antibody Anti-idotype (3E10)
Immune complexes DNAse
Immune effectors
Complement Anti-C5 (eculizumab)
Cytokines/chemokines
PDGF STI571 (gleevec, imatinib)
TNF-a Anti-TNF (infliximab)
TNFR2-Ig (rtanercept)
IL-1 IL-1ra (snakinra)
IL-10 Anti-IL-10
rIL-10
MCP Bindarit
Adhesion molecules
b 1 integrins Anti-a 4 integrin (natalizumab)
b 2 integrins Anti-CD11a (efalizumab)
Anti-CD18
ICAM-1 Anti-ICAM-1 (enlimomab)
ICAM-1 antisense oligodeoxynucleotide
(ISIS 2302, alicaforsen
Cell cycle All trans retinoic acid
R-roscovitine (CYC202)
Fibrosis/EMT Hepatocyte growth factor
Bone morphogenic protein-7
Mutant plasminogen activator inhibitor-1
Abbreviations are: PDGF, platelet-derived growth factor; TNF-a, tumor
necrosis factor-a; IL, interleukin; ICAM, intercellular adhesion molecule; MCP,
monocyte chemoattractant protein; EMT, epithelial mesenchymal transition.
tical animals) often prior to the onset of any clinically
evident manifestations of disease. Such studies are a far
cry from what occurs in clinical practice in the heteroge-
nous human population who come to treatment after dis-
ease is clinically manifest. Nonetheless, the development
pipeline of moving from experimental animal to human
trials to accepted clinical use occurred with steroids and
cytotoxic agents [22–24], showing the utility of animal
experiments. The most promising therapies for glomeru-
lonephritis, particularly those in clinical trials, will be dis-
cussed. It is also important to note that the majority of
clinical applications thus far have involved use in either
lupus nephritis or ANCA-positive vasculitides, so that a
generalization to all types of glomerulonephritis is not yet
possible.
IMPAIRMENT OF THE IMMUNE RESPONSE
B lymphocytes
Typically a coordinated effort among immune cells
is necessary for an appropriate and optimal immune
response to antigen. In any of the diseases listed in
Table 1, the immune response is no longer appropriate,
and therefore all therapeutic efforts are directed toward
deviating the immune response, such as through the use of
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the nonspecific immunosuppression listed in Table 2. Al-
though it could also be considered nonspecific, a human-
ized monoclonal antibody reactive with the CD20 antigen
on B cells (rituximab) has been used to deplete B cells in
resistant systemic lupus erythematosus (SLE). In an open
study of six patients with SLE refractory to conventional
immunosuppression, rituximab therapy was promising,
including in the three patients with diffuse proliferative
glomerulonephritis in whom proteinuria was either re-
duced or stabilized [25]. In a single patient with Wegener’s
granulomatosis and renal involvement, rituximab treat-
ment was associated with improvement in renal function
and normalization of urinalysis along with disappearance
of c-ANCA [26]. Overall, these results are encouraging,
and are stimulating further study of rituximab [27]. In
theory, any of the diseases listed in Table 2 could be fa-
vorably affected by B-cell depletion with rituximab, but
the negative effect of a general impairment in humoral
immunity would have to be assumed.
Antigen therapy
Although there is a diversity of self-antigens in SLE,
antibodies to double-stranded (ds) DNA are among the
most pathogenic, particularly to the glomerulus [28], and
hence efforts toward reducing titers of anti-dsDNA an-
tibodies are likely to be worthwhile. To accomplish this,
LJP 394 (abetimus sodium) was designed, which consists
of four 20-mer dsDNA molecules conjugated to a phara-
macologically inert triethylene glycol backbone. If naive
B-cell surface receptors reactive with dsDNA are cross-
linked by LJP 394 without coexisting T-cell help, a state
of tolerance results [29]. The multicenter LJP 394 Inves-
tigator Consortium has recently studied this drug in pa-
tients with SLE and a history of lupus nephritis. Their
results were encouraging in that they showed a length-
ening of times to renal flare and institution of high-dose
corticosteroids and/or cyclophosphamide in patients with
high-affinity anti-dsDNA antibodies, which represented
the majority of patients in this study (89%) [30]. Based
upon the encouraging results of this study, a follow-up
phase III international study is in progress in patients
with a history of lupus nephritis who have high-affinity
anti-dsDNA antibodies [30, 31].
Beyond lupus nephritis, antiglomerular basement
membrane (GBM) glomerulonephritis is a disease in
which the target antigen has been exceptionally well char-
acterized. Two epitopes have been termed EA and EB
which reside in the noncollagenous domain of the a3
chain of type IV collagen [32]. In theory, as with LJP
394, tolerance induction with antigen could be fruitful, for
which there is some support from animal studies [33, 34].
An alternative could be use of exogenous nonpathogenic
antibodies to block access of the patient’s pathogenic an-
tibodies [35].
Costimulation
Besides the signal delivered through the lymphocyte
antigen receptor, a second signal is required for a pro-
ductive immune response. Two major costimulatory path-
ways have been targeted in immunologic diseases—
the interactions of CD40 and B7 (CD80 and CD86)
on antigen-presenting cells (e.g., B cells) with their re-
spective ligands, CD40 ligand (CD154) and CD28 on
the T cell. Cytotoxic T-lymphocyte–associated antigen 4
(CTLA4) is also expressed by the T cell after activation
and has higher affinity for CD80 and CD86 than CD28
does, thereby effectively preventing activation through
CD28. The biology of these interactions has been ex-
tensively covered in recent reviews to which the inter-
ested reader is referred [36–39]. Two main strategies have
progressed the furthest in clinical studies—inhibition of
CD154 with blocking monoclonal antibodies and the use
of recombinant CTLA4 to block interaction of CD28 with
CD80 and CD86.
There are two monoclonal antibodies targeting CD154
that have been used in clinical studies, BG9588 and
IDEC-131. An open-label pilot study showed BG9588
was efficacious in eighteen patients to reduce anti-
dsDNA antibody titers and raise C3 levels [40]. In the
five patients stated to have significant hematuria, this re-
solved with treatment. The study was terminated prema-
turely because of thromboembolic events occurring in
this and concomitant protocols with BG9558. Such a phe-
nomenon was also seen in a primate model system [41].
In a phase II, double-blind study in patients with SLE,
including a minority with glomerulonephritis, IDEC-131
was well-tolerated; in particular, there was no increase in
thromboembolic events [42]. Although patients treated
with IDEC-131 had an improvement in disease activity,
so did those treated with placebo, with no difference ap-
parent among groups. The explanation for the difference
between the two different monoclonal antibodies, partic-
ularly in terms of adverse outcome of thromboembolic
events has not been explained [40].
There are two preparations of CTLA4 that have been
used clinically. The prototype is CTLA4-Ig which is a fu-
sion protein containing the extracellular portion of hu-
man CTLA4 linked to the Fc portion of human IgG1.
LEA29Y was created by mutating two amino acids, in-
creasing avidity for CD80 and CD86 and potency in in
vitro assays of T-cell responses [43]. Good data have come
out showing the efficacy of either CTLA4-Ig or LEA29Y
in rheumatoid arthritis [43, 44]. Although there are ani-
mal data supporting its efficacy [45, 46], this approach has
not yet been taken in glomerulonephritis. Clinical trials
in SLE are said to be planned [31].
In addition to the use of CTLA4 to bind CD80 and
CD86 and prevent interactions with T-cell CD28, human-
ized monoclonal antibodies to both CD80 and CD86 have
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been developed and have been shown to be effective in
primate transplant models [47, 48]. These monoclonal an-
tibodies are said to be the subject of planned clinical trials
in lupus nephritis [31, 49].
There is an increasing recognition that the kidney it-
self can be an active participant in an immune response.
For instance, CD40, as a marker of antigen-presenting
cells is up-regulated in glomerulonephritis, including lu-
pus nephritis [50]. There is now evidence in an animal
glomerulonephritis model for local CD40-CD154 inter-
actions [51]. In addition to CD40, CD80, and CD86
are also up-regulated in the kidney in human glomeru-
lonephritis [52]. Thus, therapeutic blockade of T-cell
CD28 and CD154 may extend beyond effects on lym-
phoid tissues [53] and can include disruption of interac-
tions locally.
Although the interactions of CD40 with CD154 and
CD28 with CD80/CD86 are crucial in the initiation of an
immune response, the ability of blocking this costimua-
tion to reverse an established immune response is less
certain [54]. There are animal data to support that insti-
tution of costimulatory blockade is effective after disease
is manifest [55], but other that suggest it is not [46].
Since the reality is that in glomerulonephritis of any
kind, treatment is initiated after disease is clinically ev-
ident, the true effectiveness of costimulatory blockade
will be determined only in clinical trials. Notably, the po-
tential that blocking both CD28 and CD40 interactions
in combination will be efficacious is under consideration
and is a stated goal of the United States’ National Insti-
tutes of Health–sponsored Immune Tolerance Network
[56].
Antibody/immune complexes
Once a pathogenic humoral immune response has de-
veloped, one viable therapeutic approach is to target
pathogenic antibodies either alone or in immune com-
plexes to prevent their accumulation in glomeruli. The
antigen-binding site of an antibody is termed its idiotype.
Generating an anti-idiotype antibody response can serve
to block the ability of the pathogenic antibody to bind its
antigen. Such a theory is the rationale for the use of the
monoclonal antibody 3E10, which is murine anti-dsDNA
antibody [57]. By immunizing lupus patients with 3E10,
the resultant anti-idiotype response can serve to block
dsDNA reactivity of the patients’ anti-dsDNA antibod-
ies. Notably, the 3E10 idiotype appears to be more com-
monly present in SLE patients with nephritis than those
without nephritis, providing a rationale for its use in lu-
pus nephritis [57]. Phase I studies in patients with stable
lupus nephritis have been encouraging, as five of nine pa-
tients generated a human antimurine antibody response,
including an anti-idiotype response [58].
It should be noted that although the dsDNA aptamer
LJP 394 can prevent production of a primary anti-dsDNA
response [29], other effects could be to bind already
generated anti-dsDNA antibodies, limiting the size of
immune complexes toward small soluble complexes that
inefficiently activate the complement system and/or in-
terfering with their capacity to bind intrinsic antigen [59],
some of which may be planted in situ in glomeruli [60].
Such an effect is supported by the finding that a sin-
gle dose of LJP 394 reduced anti-dsDNA antibody titers
within 1 hour of administration [61].
Another approach related to the pathogencity of the
anti-dsDNA-dsDNA immune complex to the glomeru-
lus concerns the dsDNA antigen itself when present in
immune complexes. In theory, degrading dsDNA with
DNAse could remove this critical component of autoim-
mune disease, a premise for which there is experimental
evidence in murine lupus [62]. Not only was treatment
with DNAse effective prior to the onset of clinical disease,
its efficacy was even more pronounced when glomerular
disease was active, consistent with the removal of the anti-
gen from glomeruli. In a phase I study of patients with
lupus nephritis, recombinant human DNAse therapy was
well tolerated. Unfortunately, there were no effects on
clinical markers of disease in this small trial [63].
From the preceding, it is apparent that the only spe-
cific antigen system targeted to date in human glomeru-
lonephritis has been dsDNA in lupus nephritis. To extend
this type of therapy to other glomerular diseases, it is
necessary to either know the specific antigen(s) involved
or to apply a relatively nonspecific form of therapy. As
stated, many antigens are as yet unknown, both in the
primary and secondary glomerular diseases. Thus, we are
far from applying antigen-specific therapy in most forms
of glomerulonephritis. An alternative, albeit nonspecific,
therapy is IVIG. The mechanisms of IVIG action are
complex and multiple, but include anti-idiotype effects
and the ability to clear pathogenic antibodies. Although
the role of IVIG in nonrenal diseases such as immune
thrombocytopenic purpura and Kawasaki syndrome is
becoming clear [64], whether it is effective in any form of
glomerulonephritis, such as the ANCA-related vasculi-
tides, remains to be seen [54].
IMMUNE EFFECTORS
Complement
Once the immune response has been formed and is
directed at the glomerulus, there are a host of effector
systems that come into play, each of which could rep-
resent a viable target for therapy. In all of the diseases
listed in Table 1, with the exception of the pauci-immune
glomerulonephritis associated with ANCA positivity,
complement activation products are found in associa-
tion with immunglobulin in affected glomeruli. In some
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diseases, such as lupus nephritis, membranoprolifera-
tive glomerulonephritis, postinfectious glomerulonephri-
tis, and cryoglobulinemia, systemic complement con-
sumption is evident [65]. Aside from the circumstantial
evidence for complement activation, there have been a
host of studies in the experimental animal which have
illustrated a role for complement activation in glomeru-
lonephritis [66]. Thus, targeting the complement system
is an attractive option in these diseases [67].
Since the complement system consists of three activa-
tion pathways and over 30 proteins, there are a variety
of potential targets. It is important to note that there are
aspects of this system that can protect against autoim-
munity, particularly those proteins early in the pathway,
presumably because of their ability to clear immune com-
plexes and apoptotic debris, as well as to provide signals
for an appropriate immune response [68, 69]. The com-
plement protein that has been targeted in clinical studies
has been C5. To accomplish this, a monoclonal antibody
toward C5 has been designed which prevents its cleavage
by C5 convertases, thereby eliminating the generation of
the C5a anaphylatoxin, and C5b which begins the nonezy-
matic assembly of the C5b-9 membrane attack complex.
Stimulated by a wealth of experimental data implicat-
ing C5b-9 generation on the podocyte in experimental
membranous nephropathy [70] and the utility of anti-
C5 in murine lupus [71], a multicenter phase II trial in
the United States in which 122 patients with idiopathic
membranous nephropathy were enrolled in a random-
ized placebo-controlled study of anti-C5 monoclonal an-
tibody (ecluizumab) has been completed. The primary
outcome variable in this study was urinary protein ex-
cretion. Unfortunately, there was no difference between
patients treated with anti-C5 and placebo. Because of the
short-term treatment strategy in a long-term disease, the
study design may have been insufficient to uncover a true
therapeutic effect. This is supported by the finding of an
apparent benefit in patients enrolled in an open-label ex-
tension, which is the impetus for a second planned study
with anti-C5 in membranous nephropathy.
Cytokines/chemokines
Once the immune response has involved the glomeru-
lus, the resultant inflammation is fueled by a variety of
cytokines [72]. These small soluble proteins have a diver-
sity of effects and similarly can originate from a variety
of cells including intrinsic glomerular and/or infiltrating
cells. Although there are quite a large number of those po-
tentially involved in different forms of glomerulonephri-
tis, the most relevant ones and those for which therapy
is the most advanced are listed in Table 3 and will be
discussed here.
Platelet-derived growth factors (PDGF) are a
pleiotropic group of peptide growth factors that can
be synthesized both by inflammatory cells and intrinsic
glomerular cells. These signal through cell surface PDGF
receptor tyrosine kinases (RTK). All four PDGF iso-
forms and both receptor chains are expressed in vari-
ous compartments of the normal and nephritic kidney
[73]. In experimental mesangial proliferative glomeru-
lonephritis, mesangial cells are stimulated to prolifer-
ate and produce matrix by PDGF [74]. There are a
variety of potential strategies to block PDGF [73]. Per-
haps the closest to use in humans is signal transduction
inhibitor (STI) 571 (imatinib mesylate, gleevec) which
blocks PDGF and v-Abl RTK activity [75]. Because of
its capacity to block the abnormally active Bcr-Abl on-
coprotein, it is used clinically in chronic myelogenous
leukemia. STI 571 has been shown to be efficacious in an
experimental model of mesangial proliferative glomeru-
lonephrititis [76]. Given the experience with this drug in
clinical use and its demonstrated efficacy in a relevant
animal model, this compound is the proposal of a clinical
trial in Europe in IgA nephropathy (J. Floege, personal
communication).
Tumor necrosis factor-a (TNF)-a has a number of
proinflammatory effects, including endothelial cell acti-
vation and adhesion molecule expression, activation of
neutrophils and monocyte/macrophages, and induction
of other cytokines [77]. In addition, TNF-a is proapop-
totic, which can have relevance in certain renal diseases
[78]. Strategies to block TNF-a include monoclonal an-
tibodies directed against TNF-a (infliximab) and recom-
binant soluble TNF-a receptor fused to the Fc domain
of human IgG (TNFR2-Ig) (etanercept). Both inflix-
imab and etanercept are proven therapies for rheumatoid
arthritis [79].
As far as glomerular diseases go, both neutralizing anti-
bodies to TNF-a and the use of a soluble TNFR were suc-
cessful in reducing proteinuria and glomerular neutrophil
infiltration in an anti-GBM model in rats [80]. Infliximab
has been used concomitantly with conventional therapy
in patients with ANCA-associated vasculitis with some
success. In one study, two patients with Wegener’s gran-
ulomatosis and rapidly progressive glomerulonephritis
(RPGN) achieved remission with infliximab treatment
[81]. In another study, 13 patients with renal involve-
ment had a significant decrease in serum creatinine by
14 weeks of infliximab treatment [82]. Notably, the re-
sults of a randomized trial in which etanercept was com-
pared to placebo in 180 patients with Wegener’s gran-
ulomatosis [Wegener’s Granulomatosis Etanercept Trial
(WGET)] have recently become available, which have
shown no effectiveness of etanercept in the induction or
manintenance of remissions in these patients [83]. Thus,
although two uncontrolled open-label studies with inflix-
imab were promising, these results with etanercept in
a randomized, double-masked, placebo-controlled trial,
appear to indicate TNF-a blockade will have limited
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utility in ANCA-associated glomerulonephritis. There
are also defined negatives of inhibiting TNF-a, such
as activation of tuberculosis and the development of
autoantibodies, a minority of which lead to clinically sig-
nificant lupus-like diseases [79].
The interleukins (IL) represent a large group of bio-
logically active molecules that are attractive candidates
for therapy in glomerulonephritis. IL-1 is among the most
important of the 29 interleukins (many with several iso-
forms), as it has effects on the proliferation and differ-
entiation of many cell types, including those intrinsic and
extrinsic cells involved in glomerulonephritis [77]. The
most viable approach to block IL-1 has been through the
use of a recombinant form of a naturally occurring re-
ceptor antagonist (IL-1ra) (anakinra). As with inhibiting
biological actions of TNF-a, the clinical efficacy of IL-
1 blockade with anakinra has been most established in
rheumatoid arthritis, for which this agent is an accepted
therapy [84].
There is experimental evidence in models of acute and
crescentic anti-GBM glomerulonephritis and mesangial
proliferative glomerulonephritis that IL-1ra is effective
in reducing glomerular inflammation [85–87]. However,
in established lupus nephritis in MRL/lpr mice, IL-1ra
was ineffective in reducing measures of glomerular dis-
ease activity [88]. The therapeutic role for IL-1 blockade
in human glomerulonephritis is uncertain, though, given
that it is well tolerated [89], it may have a role as an ad-
junctive therapy to other selective or nonselective agents
[54].
IL-10 is expressed by many cells and exhibits up-
regulated expression in glomerulonephritis [90]. In hu-
man SLE, elevated IL-10 levels correlate with disease
activity [91]. Administration of a blocking antibody to IL-
10 prevented lupus nephritis in the NZB/W lupus mouse
model [92]. These data have supported initial trials with
an anti-IL-10 monoclonal antibody in six patients, which
have shown such therapy to be well tolerated and ef-
fective to reduce extrarenal disease manifestations [93].
Further clinical studies with anti-IL-10 are said to be in
development [31]
In contrast, there is evidence that administration of ex-
ogenous IL-10 may have a beneficial effect in glomeru-
lonephritis [94, 95]. The explanation for this is IL-10 can
have anti-inflammatory effects by virtue of reducing pro-
duction of the Th1 cytokines, IL-2 and INF-c, as well as
suppression of neutrophil, natural killer cell, and mast cell
activity [77, 96]. A simplistic view would be that there
is a role for inhibiting IL-10 in a disease such as lupus
nephritis in which a Th2 phenotype predominates, while
in other instances such as crescentic glomerulonephritis,
even though linked by its inflammation of the glomeru-
lus, there is the possibility that providing exogenous IL-10
will be therapeutic because in this setting a Th1 pheno-
type predominates [97].
Chemokines are a subset of cytokines that control
the trafficking of particular leukocyte subpopulations
in physiologic and pathophysiologic conditions [98].
Presently, there are nearly 50 chemokine ligands and
21 receptors known. Coincident with the expansion of
the family numbers, there are ever-growing data link-
ing them to renal disease, including inflammation in
glomerulonephritis as well as progression of disease [99,
100]. Bindarit is a novel molecule with no immunosup-
pressive properties that appears to regulate cytokine
and chemokine production in acute and chronic inflam-
mation [31, 59]. In NZB/W lupus mice, it was effec-
tive in prolonging survival and protecting against renal
disease, particularly in combination with low-dose corti-
costeroids [101]. In this study, there was impressive reduc-
tion in mRNA for monocyte chemoattractant protein-
1, which is known to play an important role in experi-
mental lupus nephritis [102]. An open-label study in ten
patients with lupus nephritis demonstrated the effective-
ness of bindarit to reduce urinary protein and IL-6 excre-
tion [103]. Although there initially were plans to extend
studies with bindarit into a larger controlled study [59],
this appears to have been abandoned by the manufac-
turer [31]. Other chemokine modifying agents, such as
Met-regulated upon activation, normal T-cell expressed
and secreted (RANTES) and amino-oxypentane (AOP)-
RANTES which are CCL5/RANTES antagonists with
varying effects in experimental glomerulonephritis [104],
are still some way off before even being contemplated for
clinical use [99, 100].
Adhesion molecules
In the inflammatory response occurring in glomeru-
lonephritis, adhesion of infiltrating leukocytes to
glomerular endothelium occurs through the coordinated
expression and activity of adhesion receptor-counter re-
ceptor pairs. These interactions are also relevant to the
induction of an immune response, as they are important
for the engagement of T cells with antigen-presenting
cells; as such, they can also be considered costimula-
tory molecules in an immune response. There is a con-
siderable amount of experimental evidence implicat-
ing interactions of selectins with mucins and integrins
with immunoglobulin-like molecules as being relevant in
glomerulonephritis [105–107]. Although the number of
such interactions is large and many have been successfully
targeted in the experimental animal [107], arguably the
most relevant to glomerulonephritis and for which some
human data have been generated occurs between the b
integrins and vascular cell adhesion molecule (VCAM)-1
and intercellular adhesion molecule (ICAM)-1 [54].
The beta1 integrin, a4b 1, also known as very late anti-
gen 4 (VLA4), is present on a variety of leukocytes and
binds to VCAM-1, which is up-regulated in glomerular
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endothelium in experimental glomerulonephritis [108].
Interestingly, in human glomerulonephritis, VCAM-1
is up-regulated in proximal tubular cells but not to
an appreciable extent in endothelia [107]. Blocking
anti-a4 antibodies can prevent experimental crescentic
glomerulonephritis [108] and also reverse established dis-
ease [109], making it an attractive candidate in human
glomerulonephritis. The humanized version of this anti-
a4 monoclonal antibody (natalizumab) has been used
successfully in multicenter double-blind controlled stud-
ies in Crohn’s disease and multiple sclerosis [110, 111].
The b 2 integrins include CD11a/CD18 (lymphocyte
function–associated antigen-1) and CD11b/CD18 (Mac-
1) (complement receptor 3). A humanized monoclonal
antibody to CD18 (efalizumab, blocking CD11a/CD18
and CD11b/CD18) has been reported to reduce infiltrat-
ing leukocytes and improve vasculitic ulcers in four of
five patients with systemic vasculitis [112]. Anti-CD11a
antibodies have been used in early studies in renal trans-
plantation [113] and are promising for routine clinical use
in psoriasis [114]. Antibodiess to ICAM-1 (enlimomab)
have been used in multicenter randomized controlled
studies in patients with ischemic stroke and renal trans-
plantation with disappointing results [115, 116]. The pos-
sibility of antibody-directed complement activation on
neutrophils may limit such therapy [117]. The alternative
approach of using the antisense oligodeoxynucleotide
ISIS 2302 (alicaforsen) to limit ICAM-1 protein produc-
tion has been shown to be a potentially viable approach in
Crohn’s disease and rheumatoid arthritis [118, 119]. In-
terestingly, alternative complement pathway activation
by the oligodeoxynucleotide may also limit the use of
such an approach [120].
Overall, in spite of a body of work supporting the rel-
evance of adhesion molecules in experimental glomeru-
lonephritis, and the availability of approaches to block
them clinically, it is unclear at what point they will be
considered for use in human glomerulonephritis.
Cellular proliferation
Besides the role of cells extrinsic to the glomeru-
lus, proliferation of intrinsic glomerular cells can be of
pathogenic importance in glomerulonephritis. Prolifera-
tion of mesangial cells, such as in IgA nephropathy, lupus
nephritis and membranoproliferative glomerulonephri-
tis, and of parietal and visceral epithelial cells in crescentic
glomerulonephritis [121] can be relevant. Stimulation of
cells to proliferate involves receptor-mediated events and
entry into the cell cycle [122, 123]. Blockade of specific
growth factors, such as PDGF discussed previously, can
be one approach to limit proliferation. Other more gener-
alized approaches to limiting proliferation, including tar-
geting angiotensin II receptors, peroxisome proliferator-
activated receptors, calcium channels, and 3-hydroxy-3
methyl glutaryl-coenzyme A are strategies for which the
clinical relevance is becoming apparent [123, 124].
Studies have shown that inhibiting cyclin-dependent
kinase 2 (a cell cycle protein required for DNA synthesis)
with roscovitine reduces mesangial cell proliferation in
experimental mesangial proliferative glomerulonephritis
[125]. This was accompanied by a decrease in extracel-
lular matrix protein accumulation, and an improvement
in renal function. Of note is that R-roscovitine has also
reduced collapsing glomerulopathy in a murine model
of human immunodeficiency virus (HIV) nephropathy
[126]. R-roscovitine (SC202) is now in early clinical trials
in cancer [127, 128].
Another potentially viable approach for glomeru-
lonephritis is the use of all-trans retinoic acid (ATRA).
Like some of the therapies discussed previously that tar-
get proliferative responses, ATRA has clinical utility in
therapy of cancer and psoriasis. ATRA acts through spe-
cific cellular retinoic acid receptors to induce a vari-
ety of transcriptional effects, which can include decline
in expression of cyclins and arrest of cells at G1 [129].
ATRA has been effective to reduce various disease man-
ifestations in models of lupus nephritis [130], mesangial
proliferative glomerulonephritis [131], and anti-GBM
antibody-induced crescentic glomerulonephritis [132].
Given this background, there is the potential that ATRA
will enter clinical trials at some point in the future (S.
Shankland, personal communication).
Glomerulosclerosis/fibrosis
In the absence of spontaneous reversal of disease (such
as routinely occurs in postinfectious glomerulonephritis)
or the implementation of effective therapy (as listed in
Tables 2 and 3), the final pathway shared by all of the
glomerular diseases listed in Table 1 is the progression
to glomerulosclerosis. In addition to this glomerular phe-
notype, there is the invariant appearance of irreversible
tubulointerstitial disease, such as tubular atrophy and in-
terstitial fibrosis. This is a topic for which a considerable
amount of effort has been expended and will be covered
to emphasize its importance and to illustrate potential
therapeutic measures. The interested reader is referred
to several excellent contemporary reviews [133–137].
From work in experimental animals, three potential
targets have emerged for progressive renal disease—
interrupting the transforming growth factor (TGF)-
b1–induced signaling pathway with bone morphogenic
protein (BMP)-7 [138]; hepatocyte growth factor
(HGF)-mediated blockade of Smad activation pathways
(including those stimulated by TGF-b1) [139, 140]; and,
inhibition of plasminogen activator inhibitor (PAI)-1,
leading in aggregate to decreased matrix accumulation
[141]. In all three cases, animals were administered
human recombinant protein. The former two received
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native protein while the latter was given a dominant
negative human mutant. These raise optimism that simi-
lar approaches could be carried out in human disease.
CONCLUSION
Because the different forms of glomerulonephritis in
Table 1 have an immunologic basis, steroids and the var-
ious cytotoxic drugs listed in Table 2 have been used as
their treatment over the last 50 years. Such therapy has
been curative in some instances and palliative in many
others. However, the negatives of steroids and cytotoxics
have resulted in a quest to identify more specific targets
to which new therapy will be directed; this new and im-
proved treatment should be better at reducing or elim-
inating disease manifestations while having little to no
adverse effects.
Within the era of modern immunopathologic investiga-
tion, our understanding of the pathogenesis of glomeru-
lonephritis has advanced considerably [11]. We now
know of many possible therapeutic targets for glomeru-
lonephritis, including those listed in Table 3. It is worth
noting that these therapies are directed at a particular
underlying pathophysiologic process, such as the devel-
opment of an autoimmune humoral response or mesan-
gial proliferation, which are shared among many of the
diseases listed in Table 1. Therefore, successful therapies
may have overlapping use in glomerulonephritis diseases
that are linked by pathophysiology.
Particularly through the use of modern recombinant
technology, agents which can modify immunologic me-
diator systems have been developed and applied to the
experimental animal. The most promising of these have
made it to clinical trials in a variety of diseases, including
autoimmune diseases, cancer, and transplantation. How-
ever, even though a disease modifying biologic agent may
have clinical utility in one or more nonglomerulonephritis
diseases and experimental evidence may strongly support
that it should be used as therapy for glomerulonephritis,
accepted clinical use typically requires successful imple-
mentation in a clinical trial in the particular glomeru-
lonephritis under consideration. Unfortunately, few of
these studies have been carried out in glomerulonephritis
and only a few more are planned. The reasons for this are
complex, but include that many of the glomerulonephri-
tis diseases are relatively uncommon and have variable
outcomes, which makes them difficult and expensive to
study and not as lucrative to pharmaceutical companies
as more common “high impact” diseases. Clinicians can
help promote the study of glomerulonephritis, and fund-
ing agencies such as the United States’ National Institutes
of Health are very willing to back such translational stud-
ies. However, we still must partner with pharmaceutical
companies, which have their own restrictions. An exam-
ple of difficulty with a clinical trial in glomerulonephritis
was our four-center National Institutes of Health–funded
study of anti-C5 in proliferative lupus nephritis. After
only one patient was treated, the project was delayed
and then halted, with available resources shifted toward
examining effects of anti-C5 in cardiovascular and other
more prevalent diseases.
The sad reality is that none of the agents listed in
Table 3 is accepted therapy for glomerulonephritis.
Therefore, at least for the near term, steroids and cytotox-
ics are here to stay as treatment for glomerulonephritis;
identifying the most effective and least toxic regimens
should remain an important goal. Devoting significant
resources to taking observations made in basic research
laboratories to develop therapeutics and prove their util-
ity in human disease must be a priority to advance beyond
our dependence on steroids and cytotoxics.
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